Vismodegib
- PDF / 169,335 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 127 Views
1 S
Amenorrhea: case report A 40-year-old woman developed amenorrhea during treatment with vismodegib for basal cell carcinoma. The woman with Gorlin-Goltz syndrome had undergone multiple surgeries. She had several basal cell carcinoma on the neck and head region. Thereafter, she started receiving oral vismodegib, which showed significant response [dosage not stated]. The size of basal cell carcinoma decreased following the second cycle of vismodegib. She did not develop new skin lesions. However, after three months of vismodegib initiation, she became amenorrheic. Her pregnancy test was negative. No pain-related bleeding or secretion losses were observed. Her first menstruation was at the age 12 years and regular menses at intervals of 30–35 days. Her reproductive endocrine testing was normal, however, prolactin was 601 mUI/ml. After eight months of therapy, her skin tumours completely resolved, and till this report, no reoccurrence was observed [outcome not stated]. Russo F, et al. Amenorrhea secondary to vismodegib: An adverse event to consider especially in female patients with Gorlin-Goltz syndrome. Dermatologic Therapy 33: No. 803507460 4, Jul 2020. Available from: URL: http://doi.org/10.1111/dth.13527
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
